
Compared to chemotherapy alone, amivantamab plus chemotherapy treatment with and without lazertinib had also demonstrated positive trends in OS and ORR in patients with NSCLC.

Compared to chemotherapy alone, amivantamab plus chemotherapy treatment with and without lazertinib had also demonstrated positive trends in OS and ORR in patients with NSCLC.

Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.

Many patients face significant challenges in accessing their specialty medications, which highlights the importance of pharmacy-deployed patient navigation programs designed to help resolve nonclinical, system-related barriers to care.

Patients with previously untreated HLA-A*02:01+ mUM saw improvements in OS, PFS, and ctDNA clearance.

Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both pathological complete response and major pathologic response rates.

Vanderbilt Specialty Pharmacy and Takeda Oncology are reaching across silos and entering an innovative partnership to improve patient care across the entire medication journey.

According to investigators, additional research is necessary to further understand how lutetium impacts overall survival in patients with metastatic prostate cancer.

Jack Mozloom, vice president of Public Affairs at the National Community Pharmacists Association (NCPA), speaks with Matt Seiler, general counsel at NCPA, about the current PBM litigation at the 2023 NCPA Convention.

This is the first phase 3 trial to evaluate a KRAS G12C-inhibitor plus an anti-epidermal growth factor receptor antibody for this type of colorectal cancer.

The novel combination met the co-primary endpoints of progression-free survival and overall survival during the CheckMate -901 trial, also demonstrating sizeable improvement in objective response.

Oncology leaders and pharma representatives discuss collaboration best practices.

Not only did taletrectinib shrink tumors in 92% of patients who were tyrosine kinase inhibitor -naïve, but 89.5% of patients continued to respond to treatment at 12 months.

Compared to endocrine therapy alone, the combination of ribociclib and endocrine therapy lowered the risk of cancer recurrence in patients with early breast cancer by 25.2%.

Subcutaneous nivolumab had demonstrated noninferiority of Cavgd28, Cminss, and ORR compared to the intravenous form of treatment.

Areas of focus for specialty medications include biosimilars, cancer treatments, and drugs across disease states such as inflammatory conditions, HIV, and multiple sclerosis.

Medically integrated dispensing specialty pharmacies can connect patient medical and pharmacy records to improve medication adherence and help patients to safely stay on them for longer.

Bimekizumab is a novel, humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-7A and IL-17F, which are key cytokines driving inflammatory processes in plaque psoriasis.

According to the authors, identifying the degree of disagreement with physicians’ deprescribing recommendations can improve the communication among older adults and their physicians.

Pharmacy Technician Day celebrates the myriad contributions of the unsung heroes of health care.

A subcutaneous injection of ocrelizumab was markedly effective at suppressing brain lesions in patients with multiple sclerosis, according to data from a phase 3 trial.

Karline Peal, MBA of Vanderbilt Ingram Cancer Center discusses the positive impact technology has had in health care and how it can be implemented in the future.

Although education and training have historically been considered the primary factors influencing pay, the survey results challenge this notion.

A single-center experience at a tertiary medical center precision medicine clinic provides insight.

Community pharmacies are ideal locations to identify and recruit underrepresented patients for clinical trials.

In the first systematic review using statistical methods, investigators found switching from a reference biologic to a biosimilar was comparable in safety, but no conclusion on immunogenicity could be drawn.

The intravenous formulation of secukinumab is administered in monthly 30-minute, weight-based dosing and requires no pre-medication or lab monitoring.

The use of psilocybin, repeated at a low dose, could offer a new form of treatment for individuals with differing forms of mental disorders.

Lack of awareness, cultural beliefs, and physician preferences may influence whether minority patients receive palliative care during metastatic breast cancer treatment.

Although respondents reported no impacts on patient safety, workload significantly increased during the COVID-19 pandemic and led to major burnout challenges.

Nedosiran (Rivfloza; Novo Nordisk Inc) injection is designed to inhibit the expression of liver enzyme lactate dehydrogenases leading to oxalate overproduction in patients 9 years of age and older with PH1.